Sana Biotechnology (SANA) Cash & Equivalents (2020 - 2026)

Sana Biotechnology has reported Cash & Equivalents for 7 years, with the latest figure at $83.8 million in Q1 2026.

• Quarterly Cash & Equivalents fell 12.83% year-over-year to $83.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $83.8 million (down 12.83% YoY) and the FY2025 annual result came in at $71.9 million, down 43.66% from the prior year.
• Cash & Equivalents climbed to $83.8 million in Q1 2026 per SANA's latest filing, from $71.9 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $194.7 million in Q2 2022 and troughed at $71.3 million in Q2 2025.
• A 5-year average of $138.4 million and a median of $135.0 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents plunged 74.89% in 2022, then climbed 10.34% in 2024.
• Over 5 years, Cash & Equivalents stood at $176.8 million in 2022, then fell by 24.47% to $133.5 million in 2023, then retreated by 4.46% to $127.6 million in 2024, then tumbled by 43.66% to $71.9 million in 2025, then advanced by 16.6% to $83.8 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $83.8 million, $71.9 million, and $103.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.